

June 18, 2013

# **JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes**

## **Combination of BD's proprietary technologies represents critical step toward artificial pancreas**

FRANKLIN LAKES, N.J. and NEW YORK, June 18, 2013 /PRNewswire/ -- JDRF and BD (Becton, Dickinson and Company) (NYSE:BDX) are accelerating the development of new products that combine BD's proprietary insulin infusion and glucose sensing technologies through a new collaboration announced today. This new, three-year commitment is an extension of existing JDRF-BD collaborations focused on type 1 diabetes (T1D).

Many patients with T1D not only take daily insulin via an insulin pump – requiring a catheter to be placed in the body for a number of days – but are also checking their glucose levels via a continuous glucose monitor (CGM), which also requires a catheter-like sensor to be placed in the body for a number of days.

While BD has been working to improve the products used for insulin infusion and CGM, the new collaboration with JDRF will enable additional research to develop a single optimized device that will perform both functions and eliminate the need and complexities of multiple in-dwelling catheters. The ability to perform these discrete metabolic actions automatically and accurately, with little patient intervention, defines the artificial pancreas concept.

"Providing the best tools that not only improve patient care, but ease the daily burden of managing diabetes are important goals for BD and JDRF," said Linda Tharby, President, BD Medical – Diabetes Care. "This latest collaboration with JDRF demonstrates both parties' commitment to improve patients' experiences and outcomes. Combining these novel technologies will address two key components of an advanced artificial pancreas system."

"As the world's largest charitable funder of type 1 diabetes research, JDRF is committed to advancing therapies that improve the lives of people living with this disease," said Jeffrey Brewer, President and Chief Executive Officer of JDRF. "We are excited to continue our collaboration with BD and support efforts to develop novel technologies enabling advanced artificial pancreas systems that will both measure glucose and administer insulin. Joining these capabilities into a single solution will address significant patient needs and help reduce the daily burden of managing type 1 diabetes."

T1D is an autoimmune disease in which the body's pancreas stops producing insulin, a hormone needed to turn food into energy. BD's culture of innovation and continuous improvement has enhanced the patient experience to help improve therapy and outcomes for people with diabetes worldwide. BD devices support earlier initiation and better adherence to prescribed therapies to help all diabetes patients live healthier lives.

## About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit [www.bd.com](http://www.bd.com).

## About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently sponsoring \$530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than \$110 million to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012, *Forbes* magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness. For more information, please visit [jdrf.org](http://jdrf.org).

### Contacts:

#### JDRF

Tara Wilcox-Ghanoonparvar

(212) 479-7524

[twilcox-ghanoonparvar@jdrf.org](mailto:twilcox-ghanoonparvar@jdrf.org)

#### BD

Lindsay Roman

(201) 847-4312

[lindsay\\_roman@bd.com](mailto:lindsay_roman@bd.com)

SOURCE BD (Becton, Dickinson and Company); JDRF